Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. (RTSN) priced its initial public offering on Oct 9, 2026 at $12.00 per share, raising $45M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $100M. Leerink Partners was lead-left underwriter, joined by Guggenheim, Oppenheimer and Titan Partners. DLA Piper advised the company and Covington & Burling advised the underwriters.

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing medicines for hypertension and other cardiovascular diseases. Its candidate RTN-001 is a once-daily oral PDE-5 inhibitor designed to lower blood pressure by potentiating nitric oxide signaling.

Status

IPO

Ticker

RTSN

Exchange

Nasdaq Capital Market

Priced

Oct 9, 2026

IPO price

$12.00

Raised

$45M

Market cap at IPO price

$100M

First filed

Sep 18, 2026

Underwriters

Leerink Partners, Guggenheim, Oppenheimer and Titan Partners

Company counsel

DLA Piper

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

VA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.